Name : Human TRAIL Trimer Protein
Product Source :
Recombinant Human TRAIL Trimer Protein is expressed from HEK293 with His tag and Flag tag at the N-Terminus. It contains Gly118-Gly281.[Accession | P50591-1]
Molecular Weight :
The protein has a predicted MW of 60 kDa. Due to glycosylation, the protein migrates to 55-65 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 90% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt.-80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human TRAIL Trimer on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Human TRAIL Trimer is greater than 90% as determined by SEC-HPLC. ELISA Data Immobilized Human TRAIL Trimer, His Tag at 2μg/ml (100μl/well) on the plate. Dose response curve for Human TRAIL R1, hFc Tag with the EC50 of 4.9ng/ml determined by ELISA.
Background :
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily that can initiate the apoptosis pathway by binding to its associated death receptors DR4 and DR5. The activation of the TRAIL pathway in inducing tumor-selective apoptosis leads to the development of TRAIL-based cancer therapies, which include recombinant forms of TRAIL, TRAIL receptor agonists, and other therapeutic agents.
Synonyms :
Apo-2L; TRAIL; CD253; TNFSF10; Apo-2 ligand; APO2L; TL2
References & Citations :
(1)Yuan X, Gajan A, Chu Q, Xiong H, Wu K, Wu GS. Developing TRAIL/TRAIL death receptor-based cancer therapies. Cancer Metastasis Rev. 2018 Dec;37(4):733-748. doi: 10.1007/s10555-018-9728-y. PMID: 29541897; PMCID: PMC6138568.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
IL-1 beta ProteinMedChemExpress
EpCAM/TROP1 ProteinMedChemExpress
Popular categories:
PTPN2
TNF-alpha